Imaging EGFR and HER2 by PET and SPECT: A Review

Corcoran, Emily B.; Hanson, Robert N.

doi:10.1002/med.21299

Cited by 52 publications

(49 citation statements)

References 140 publications

(328 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, clinical outcome and early therapeutic response have been related to 18 F-FDG PET/CT and more recently 18 F-39-deoxy-39-18 F-fluorothymidine and 18 F-fluromisonidazole for treatment with radiochemotherapy (17)(18)(19)(20), but little is known about prediction if radiotherapy is combined with EGFR inhibitors. Many possibilities have been investigated for facilitating imaging of EGFR by PET and SPECT (21) in search for prognostic and predictive markers, but it has not yet been proven clinically relevant.…”

mentioning

confidence: 99%

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

et al. 2014

View full text Add to dashboard Cite

mentioning

confidence: 99%

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

et al. 2014

View full text Add to dashboard Cite

“…For instance, endogenous ligands will inevitably induce biological effects such as increased cell proliferation and enhanced cell survival and could also stimulate tumor growth. In addition, the endogenous ligand will theoretically preclude the preferential uptake of the radiolabeled ligand versus the unlabeled ligand in animal tumor models and therefore reduce contrast ratio of the tumor PET or SPECT images [42]. These limitations hinder the clinical translation of HGF-based molecular imaging and need be addressed in the future.…”

Section: Reviewmentioning

confidence: 99%

Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review

Han

Wang

et al. 2017

EJNMMI Res

View full text Add to dashboard Cite

BackgroundMesenchymal–epithelial transition factor also named c-MET is a receptor tyrosine kinase for the hepatocyte growth factor that plays a pivotal role in tumorigenesis. c-MET-targeted therapies have been tested in preclinical models and patients, with significant benefits for cancer treatment. In recent years, many studies have shown that the expression level and activation status of c-MET are closely correlated to c-MET-targeted therapy response and clinical prognosis, thus highlighting the importance of evaluating the c-MET status during and prior to targeted therapy. Molecular imaging allows the monitoring of abnormal alterations of c-MET in real time and in vivo.ResultsIn this review, we initially summarize the recent advances in c-MET-targeted molecular imaging, with a special focus on the development of imaging agents ranging in size from monoclonal antibody to small molecule. The aim of this review is to report the preclinical results and clinical application of all molecular imaging studies completed until now for in vivo detection of c-MET in cancer, in order to be beneficial to development of molecular probe and the combination of molecular imaging technologies for in vivo evaluation of c-MET. Various molecular probe targeted to c-MET possesses distinctive advantages and disadvantages. For example, antibody-based probes have high binding affinity but with long metabolic cycle as well as remarkable immunogenicity.ConclusionsAlthough studies for c-MET-targeted molecular imaging have made many important advances, most of imaging agents specifically target to extracellular area of c-MET receptor; however, it is difficult to reflect entirely activation of c-MET. Therefore, small molecule probes based on tyrosine kinase inhibitors, which could target to intracellular area of c-MET without any immunogenicity, should be paid more attention.

show abstract

“…Tumor cell proliferation can be depicted by the thymidine analog 18 F-fluorothymidine, which has been validated against histopathologic specimens in a broad variety of solid tumors and lymphomas (8)(9)(10). Apart from tracers depicting biometabolic tumor characteristics such as angiogenesis and apoptosis, radiotracers assessing tumor receptor expression, such as human epithelial growth factor receptor 2 and the epidermal growth factor receptor (EGFR), are increasingly being applied (11)(12)(13)(14).…”

Section: Functional and Molecular Imaging Modalities Currently Availablementioning

confidence: 99%

Imaging-Based Treatment Adaptation in Radiation Oncology

2015

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) understand the clinical implications of tumor characterization using different PET tracers before and during radiotherapy or chemoradiotherapy; (2) discuss the role of other functional imaging modalities (CT and MRI) in current oncology practice; and (3) introduce additional applications of PET imaging, such as in high-energy proton-beam therapy.

show abstract

Imaging EGFR and HER2 by PET and SPECT: A Review

Cited by 52 publications

References 140 publications

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review

Imaging-Based Treatment Adaptation in Radiation Oncology

Contact Info

Product

Resources

About

Imaging EGFR and HER2 by PET and SPECT: A Review

Cited by 52 publications

References 140 publications

Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab′)2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab′)2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review

Imaging-Based Treatment Adaptation in Radiation Oncology

Contact Info

Product

Resources

About

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model